Almotriptan

Selective 5-HT1B/1D receptor agonist (triptan) that constricts dilated cranial vessels and inhibits neurogenic inflammation, relieving acute migraine attacks with or without aura. Almotriptan also blocks the release of vasoactive neuropeptides from trigeminal nerve endings, addressing a key part of migraine pathophysiology rather than pain perception alone. It is most effective when taken early in an attack and can be re-dosed if the headache recurs, up to the maximum daily dose. Its receptor selectivity gives it a lower reported incidence of chest and throat tightness than some older triptans.